Interleukin-6 in Rheumatoid Arthritis

Eleonora Nucera, Franco Pandolfi, Laura Franza, Gloria Andriollo, Valentina Carusi, Simona Altamura

Research output: Contribution to journalArticle


The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.
Original languageEnglish
Pages (from-to)5238-N/A
JournalInternational Journal of Molecular Sciences
Publication statusPublished - 2020


  • Antibodies, Monoclonal
  • Arthritis, Rheumatoid
  • Disease Progression
  • Humans
  • IL-6
  • Interleukin-6
  • Molecular Targeted Therapy
  • Signal Transduction
  • inflammation
  • rheumatoid arthritis


Dive into the research topics of 'Interleukin-6 in Rheumatoid Arthritis'. Together they form a unique fingerprint.

Cite this